CTX Stock Overview
A biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Captor Therapeutics Spolka Akcyjna Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł81.00 |
| 52 Week High | zł132.00 |
| 52 Week Low | zł59.00 |
| Beta | 0.61 |
| 11 Month Change | 2.79% |
| 3 Month Change | 8.29% |
| 1 Year Change | -34.68% |
| 33 Year Change | -57.37% |
| 5 Year Change | n/a |
| Change since IPO | -52.90% |
Recent News & Updates
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Jul 13
We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10Recent updates
Here's Why We're Not Too Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Jul 13We Think Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Drive Business Growth
Mar 10We're Not Worried About Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn
Oct 03Here's Why We're Not At All Concerned With Captor Therapeutics Spolka Akcyjna's (WSE:CTX) Cash Burn Situation
Mar 13Companies Like Captor Therapeutics Spolka Akcyjna (WSE:CTX) Can Afford To Invest In Growth
Jun 15Shareholder Returns
| CTX | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | 1.3% | 1.7% | -0.7% |
| 1Y | -34.7% | -10.0% | 16.7% |
Return vs Industry: CTX underperformed the Polish Biotechs industry which returned -10% over the past year.
Return vs Market: CTX underperformed the Polish Market which returned 16.7% over the past year.
Price Volatility
| CTX volatility | |
|---|---|
| CTX Average Weekly Movement | 6.4% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.3% |
| 10% least volatile stocks in PL Market | 3.4% |
Stable Share Price: CTX has not had significant price volatility in the past 3 months.
Volatility Over Time: CTX's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 105 | Tom Shepherd | www.captortherapeutics.com |
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has various therapeutic molecules in the preclinical stage.
Captor Therapeutics Spolka Akcyjna Fundamentals Summary
| CTX fundamental statistics | |
|---|---|
| Market cap | zł377.69m |
| Earnings (TTM) | -zł65.79m |
| Revenue (TTM) | zł16.16m |
23.4x
P/S Ratio-5.7x
P/E RatioIs CTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CTX income statement (TTM) | |
|---|---|
| Revenue | zł16.16m |
| Cost of Revenue | zł7.39m |
| Gross Profit | zł8.78m |
| Other Expenses | zł74.57m |
| Earnings | -zł65.79m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Sep 05, 2024
| Earnings per share (EPS) | -14.11 |
| Gross Margin | 54.29% |
| Net Profit Margin | -407.07% |
| Debt/Equity Ratio | 0% |
How did CTX perform over the long term?
See historical performance and comparison